The rapid expansion of clinical trial capacity in China over the past decade has been concentrated in the country's top-tier medical institutions, according to a new analysis published in the journal Nature Medicine. The finding raises concerns that the growth may not translate into more equitable access to biomedical innovation for patients outside major academic centers.
Clinical trials are a critical pathway for patients to gain access to new drugs, devices, and therapies before they become widely available. The analysis notes that China has seen a sharp increase in trial activity in recent years, reflecting broader investment in biomedical research and a growing role in global drug development. But the benefits of that growth have not been evenly distributed.
According to the analysis, the expansion has clustered in a relatively small number of elite hospitals and research centers, typically located in major cities. These institutions have the infrastructure, specialized staff, and patient volume needed to run complex studies, which makes them natural hubs for trial activity. The concentration, however, means that patients treated elsewhere — including those in smaller cities and rural areas — are less likely to encounter opportunities to enroll in trials.
The authors argue that this pattern needs careful management if the goal is to improve equitable access. Without deliberate efforts to broaden the network of participating sites, the growth in trial capacity could reinforce existing gaps in healthcare access rather than narrow them. The analysis does not call for slowing the expansion, but suggests that how the capacity is distributed matters as much as how much of it exists.
The findings come as China plays an increasingly prominent role in global clinical research. The country's large patient population, improving regulatory environment, and growing pharmaceutical industry have made it an attractive location for trials sponsored by both domestic and multinational companies. That trend has benefits for patients who can enroll, and it also gives Chinese researchers and regulators more experience with cutting-edge therapies.
Yet the same factors that make top-tier institutions attractive for trials — specialized expertise, advanced equipment, and dense patient populations — can also make it harder to extend trial networks to less well-resourced settings. Smaller hospitals may lack the staff, training, or administrative capacity to participate, and sponsors may be reluctant to take on the additional costs and complexity of managing more sites.
The analysis in Nature Medicine highlights a broader question for health systems around the world: whether expanding research capacity automatically improves access to care, or whether it mainly benefits patients who are already treated at leading centers. In China's case, the evidence suggests that the answer depends on policy choices about where trials are located and how participation is encouraged.
For patients, the stakes are practical. Trial enrollment can offer access to therapies that are not yet on the market, often at no cost, and can provide closer monitoring than routine care. When trials are concentrated in a few cities, patients elsewhere may face travel, cost, and logistical barriers that make participation unrealistic.
The analysis points to the need for careful management of trial expansion, including strategies to build capacity at a wider range of institutions and to ensure that the benefits of biomedical innovation reach beyond elite academic centers. It does not specify particular policies, but frames the issue as one that requires attention from regulators, sponsors, and health system leaders alike.
As China's clinical research footprint continues to grow, the way that growth is distributed will shape who gains access to new treatments and who does not. The Nature Medicine analysis suggests that without intentional efforts to broaden participation, the country's impressive expansion in trial capacity may leave significant portions of its patient population on the sidelines.
8
